Related references
Note: Only part of the references are listed.Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy
Qiyu Fang et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2023)
Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
Taichi Miyawaki et al.
SUPPORTIVE CARE IN CANCER (2022)
Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer
Naoki Shijubou et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer
Taichi Miyawaki et al.
THORACIC CANCER (2022)
Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report
Clelia Madeddu et al.
DIAGNOSTICS (2022)
The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival
Jenny G. Turcott et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2021)
Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy
Cinzia Baldessari et al.
CLINICAL NUTRITION ESPEN (2021)
Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab
Taisuke Araki et al.
THORACIC CANCER (2021)
Cachexia as Evidence of the Mechanisms of Resistance and Tolerance during the Evolution of Cancer Disease
Antonio Maccio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis
Han-Yu Deng et al.
NUTRITION (2021)
COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
Antonio Maccio et al.
JOURNAL OF OVARIAN RESEARCH (2021)
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
Pascaline Boudou-Rouquette et al.
EBIOMEDICINE (2021)
Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study
Marta Tenuta et al.
CANCERS (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy
Yixing Wang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab
Juliette H. R. J. Degens et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2021)
Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study
Konstantinos Rounis et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines
J. Arends et al.
ESMO OPEN (2021)
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study
KenjiY Morimoto et al.
ONCOIMMUNOLOGY (2021)
Blocking inflammation to improve immunotherapy of advanced cancer
Antonio Maccio et al.
IMMUNOLOGY (2020)
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
Kazuki Takada et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
Mariko Tsukagoshi et al.
MEDICINE (2020)
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
Alessio Cortellini et al.
SCIENTIFIC REPORTS (2020)
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer
Mila P. Petrova et al.
BIOSCIENCE TRENDS (2020)
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors
Benoit Roch et al.
LUNG CANCER (2020)
The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
Taichi Matsubara et al.
JOURNAL OF THORACIC DISEASE (2020)
Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer
M. P. Petrova et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis
Jing Jin et al.
BMJ OPEN (2020)
Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
Wenxian Wang et al.
FRONTIERS IN ONCOLOGY (2020)
Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis
Jiajun Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
S. Peters et al.
ANNALS OF ONCOLOGY (2019)
Prognostic Value of Sarcopenia in Lung Cancer A Systematic Review and Meta-analysis
Ming Yang et al.
CHEST (2019)
Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors
Tao Jiang et al.
LUNG CANCER (2019)
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
Naoya Nishioka et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
Florian R. Greten et al.
IMMUNITY (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer
J. H. R. J. Degens et al.
LUNG CANCER (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients
Valentina Magri et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Fumihiro Shoji et al.
LUNG CANCER (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A hypothesis-generator preliminary report
Alessio Cortellini et al.
THORACIC CANCER (2019)
Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study
Takayuki Shiroyama et al.
SCIENTIFIC REPORTS (2019)
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer A Meta-analysis and Individual Patient-Level Analysis
Yunfang Yu et al.
JAMA NETWORK OPEN (2019)
Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer
Takayuki Shiroyama et al.
CANCER MEDICINE (2018)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
E. E. Vokes et al.
ANNALS OF ONCOLOGY (2018)
Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers
Lauriane Chambard et al.
BONE (2018)
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
David C. Turner et al.
CLINICAL CANCER RESEARCH (2018)
Is increased neutrophil lymphocyte ratio remarking the inflammation in sarcopenia?
Zeynel Abidin Ozturk et al.
EXPERIMENTAL GERONTOLOGY (2018)
Chronic inflammation and sarcopenia: A regenerative cell therapy perspective
Jagadish K. Chhetri et al.
EXPERIMENTAL GERONTOLOGY (2018)
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
Alessandro Russo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Changes in Nutritional Status impact immune Cell Metabolism and Function
Yazan Alwarawrah et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cancer-associated cachexia
Vickie E. Baracos et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
S. N. Gettinger et al.
NATURE COMMUNICATIONS (2018)
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy
Alessio Cortellini et al.
THORACIC CANCER (2018)
Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
Jibin Li et al.
MEDICAL SCIENCE MONITOR (2018)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Inflammation and sarcopenia: A systematic review and meta-analysis
Giulia Bano et al.
MATURITAS (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Connecting the Metabolic and Immune Responses to Cancer
Thomas R. Flint et al.
TRENDS IN MOLECULAR MEDICINE (2017)
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Florie Bertrand et al.
NATURE COMMUNICATIONS (2017)
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw et al.
CANCER DISCOVERY (2017)
Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study
Maurizio Muscaritoli et al.
ONCOTARGET (2017)
Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy
F. Bozzetti
ANNALS OF ONCOLOGY (2017)
Targeting the PD-1/PD-L1 axis in non-small cell lung cancer
Rajiv Kumar et al.
CURRENT PROBLEMS IN CANCER (2017)
Metabolic Instruction of Immunity
Michael D. Buck et al.
CELL (2017)
Nutritional effects on T-cell immunometabolism
Sivan Cohen et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
Thomas R. Flint et al.
CELL METABOLISM (2016)
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
Laurent Dercle et al.
EUROPEAN JOURNAL OF CANCER (2016)
Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review
Shlomit Strulov Shachar et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immunometabolism of regulatory T cells
Ryan Newton et al.
NATURE IMMUNOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value
Drazena Srdic et al.
SUPPORTIVE CARE IN CANCER (2016)
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Xiangjiao Meng et al.
CANCER TREATMENT REVIEWS (2015)
Immunosuppression associated with chronic inflammation in the tumor microenvironment
Dingzhi Wang et al.
CARCINOGENESIS (2015)
Muscle wastingas main evidence of energy impairment in cancer cachexia: future therapeutic approaches
Clelia Madeddu et al.
FUTURE ONCOLOGY (2015)
Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors
Claribel P. Simmons et al.
LUNG CANCER (2015)
Inflammation and cancer: advances and new agents
Shanthini M. Crusz et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study
Antonio Maccio et al.
HAEMATOLOGICA (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Novel Role for Tumor-Induced Expansion of Myeloid-Derived Cells in Cancer Cachexia
Alex G. Cuenca et al.
JOURNAL OF IMMUNOLOGY (2014)
Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK
James P. White et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
Syed H. Jafri et al.
BMC CANCER (2013)
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
Donald C. McMillan
CANCER TREATMENT REVIEWS (2013)
Prognostic Factors in Patients with Advanced Cancer: A Comparison of Clinicopathological Factors and the Development of an Inflammation-Based Prognostic System
Barry J. Laird et al.
CLINICAL CANCER RESEARCH (2013)
Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?
Pura Munoz-Canoves et al.
FEBS JOURNAL (2013)
Modulation of neutrophil granulocytes in the tumor microenvironment: Mechanisms and consequences for tumor progression
Claudia A. Dumitru et al.
SEMINARS IN CANCER BIOLOGY (2013)
Sarcopenia, obesity, and natural killer cell immune senescence in aging: Altered cytokine levels as a common mechanism
Charles T. Lutz et al.
AGING-US (2012)
IL-6 activates STAT5 in T cells
Aurelie Jeanne Tormo et al.
CYTOKINE (2012)
Inflammation and ovarian cancer
Antonio Maccio et al.
CYTOKINE (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Definition and classification of cancer cachexia: an international consensus
Kenneth Fearon et al.
LANCET ONCOLOGY (2011)
Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis
Vickie E. Baracos et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2010)
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Suzanne Ostrand-Rosenberg
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03
Satoshi Teramukai et al.
EUROPEAN JOURNAL OF CANCER (2009)
A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care
Marina Mourtzakis et al.
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM (2008)
Fuel feeds function: Energy metabolism and the T-cell response
CJ Fox et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer
B Almand et al.
JOURNAL OF IMMUNOLOGY (2001)
Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer
G Mantovani et al.
JOURNAL OF IMMUNOTHERAPY (2000)
Share Paper
